BiotechTube

Vaginal estrogen + Placebo

Pre-clinicalTerminated
0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pelvic Organ Prolapse

Conditions

Pelvic Organ Prolapse

Trial Timeline

May 1, 2012 → Mar 2, 2023

NCT ID
NCT01648751

About Vaginal estrogen + Placebo

Vaginal estrogen + Placebo is a pre-clinical stage product being developed by Pfizer for Pelvic Organ Prolapse. The current trial status is terminated. This product is registered under clinical trial identifier NCT01648751. Target conditions include Pelvic Organ Prolapse.

What happened to similar drugs?

3 of 6 similar drugs in Pelvic Organ Prolapse were approved

Approved (3) Terminated (1) Active (3)
✅Solifenacin + PlaceboAstellas PharmaApproved
✅Conjugated Estrogens Cream + Placebo CreamPfizerApproved
✅Sevoflurane + propofol + remifentanilBaxterApproved
🔄AzithromycinPfizerPhase 3
🔄Ofloxacin + Avelox (Moxifloxacin, BAY12-8039)BayerPhase 3
🔄Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & MetronidazoleBayerPhase 3

Hype Score Breakdown

Clinical
3
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01648751Pre-clinicalTerminated

Competing Products

11 competing products in Pelvic Organ Prolapse

See all competitors
ProductCompanyStageHype Score
Solifenacin + PlaceboAstellas PharmaApproved
35
BGS649 + PlaceboNovartisPhase 2
27
Tanezumab + PlaceboPfizerPhase 2
35
AzithromycinPfizerPhase 3
40
Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tabletPfizerPhase 2
27
Conjugated Estrogens Cream + Placebo CreamPfizerApproved
43
BAY1834845 + PlaceboBayerPhase 1
26
Ofloxacin + Avelox (Moxifloxacin, BAY12-8039)BayerPhase 3
37
Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & MetronidazoleBayerPhase 3
37
Dienogest (BAY86-5258, Visanne)BayerPre-clinical
23
Sevoflurane + propofol + remifentanilBaxterApproved
40